[{"orgOrder":0,"company":"Intelligem Therapeutics Australia Pty Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"AUSTRALIA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"IG3018","moa":"Undisclosed","graph1":"Rheumatology","graph2":"Phase I\/ Phase II","graph3":"Intelligem Therapeutics Australia Pty Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intelligem Therapeutics Australia Pty Ltd. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Intelligem Therapeutics Australia Pty Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Urica Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dontinurad","moa":"URAT1","graph1":"Rheumatology","graph2":"Phase I\/ Phase II","graph3":"Urica Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Urica Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Urica Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ALN-XDH","moa":"Xanthine dehydrogenase\/oxidase messenger RNA (XDH mRNA)","graph1":"Rheumatology","graph2":"Phase I\/ Phase II","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alnylam Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adaptive Phage Therapeutics","sponsor":"Mayo Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rheumatology","graph2":"Phase I\/ Phase II","graph3":"Adaptive Phage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adaptive Phage Therapeutics \/ Mayo Clinic","highestDevelopmentStatusID":"7","companyTruncated":"Adaptive Phage Therapeutics \/ Mayo Clinic"},{"orgOrder":0,"company":"Adaptive Phage Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rheumatology","graph2":"Phase I\/ Phase II","graph3":"Adaptive Phage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adaptive Phage Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Adaptive Phage Therapeutics \/ Undisclosed"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : The financing round will support the advancement of Phase 3 evaluating, FYU-981 (dotinurad), a next-generation, once daily oral, URAT1 inhibitor for the treatment of gout.

                          Product Name : FYU-981

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          September 30, 2025

                          Lead Product(s) : Dotinurad,Allopurinol

                          Therapeutic Area : Rheumatology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Novo Holdings

                          Deal Size : $205.0 million

                          Deal Type : Series A Financing

                          blank

                          02

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : SAP-001 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Gout.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          December 11, 2024

                          Lead Product(s) : SAP-001

                          Therapeutic Area : Rheumatology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Intelligem Therapeutics Australia Pty Ltd.

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          Intelligem Therapeutics Australia Pty Ltd.

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          Details : IG3018 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Hyperuricemia.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          March 15, 2024

                          Lead Product(s) : IG3018

                          Therapeutic Area : Rheumatology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Dontinurad is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Gout.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 28, 2023

                          Lead Product(s) : Dontinurad

                          Therapeutic Area : Rheumatology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Recombinant Anti-IL-1 Humanized Monoclonal Antibody is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Gout.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          October 20, 2022

                          Lead Product(s) : Recombinant Anti-IL-1 Humanized Monoclonal Antibody

                          Therapeutic Area : Rheumatology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Lead Product(s) : Genakumab

                          Therapeutic Area : Rheumatology

                          Study Phase : Phase I/ Phase II

                          Sponsor : Huashan Hospital | Hainan General Hospital | Linyi People's Hospital | The Second Affiliated Hospital of Chongqing Medical University | Changhai Hospital | The First Affiliated Hospital with Nanjing Medical University | Shengjing Hospital | Affiliated Hos

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Genakumab is a Antibody drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Gout.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          April 14, 2022

                          Lead Product(s) : Genakumab

                          Therapeutic Area : Rheumatology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Huashan Hospital | Hainan General Hospital | Linyi People's Hospital | The Second Affiliated Hospital of Chongqing Medical University | Changhai Hospital | The First Affiliated Hospital with Nanjing Medical University | Shengjing Hospital | Affiliated Hos

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : This drug candidate is currently being evaluated in phase I/ phase II clinical studies for the treatment of Arthritis, Infectious.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          March 07, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Rheumatology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : ALN-XDH is a Oligonucleotide drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Gout.

                          Product Name : Undisclosed

                          Product Type : Oligonucleotide

                          Upfront Cash : Inapplicable

                          February 25, 2022

                          Lead Product(s) : ALN-XDH

                          Therapeutic Area : Rheumatology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : This drug candidate is currently being evaluated in phase I/ phase II clinical studies for the treatment of Arthritis, Infectious.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          March 08, 2021

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Rheumatology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Mayo Clinic

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : D-0120 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Hyperuricemia.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          April 23, 2019

                          Lead Product(s) : D-0120

                          Therapeutic Area : Rheumatology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank